ArticleNeurology and therapy2025

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

Takashi Yamamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.